Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Calithera Biosci Com (CALA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 209,462
  • Shares Outstanding, K 35,990
  • Annual Sales, $ 25,960 K
  • Annual Income, $ -27,830 K
  • 36-Month Beta 2.48
  • Price/Sales 8.12
  • Price/Cash Flow N/A
  • Price/Book 1.43

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.41
  • Number of Estimates 3
  • High Estimate -0.21
  • Low Estimate -0.58
  • Prior Year -0.17
  • Growth Rate Est. (year over year) -141.18%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.70 +23.83%
on 09/21/18
6.49 -10.34%
on 10/12/18
+1.02 (+21.25%)
since 09/17/18
3-Month
4.05 +43.70%
on 07/30/18
6.49 -10.34%
on 10/12/18
+1.32 (+29.33%)
since 07/17/18
52-Week
4.05 +43.70%
on 07/30/18
18.35 -68.28%
on 10/18/17
-11.93 (-67.21%)
since 10/17/17

Most Recent Stories

More News
Market Trends Toward New Normal in Nasdaq, Calithera Biosciences, Pinnacle West Capital, National Instruments, American Vanguard, and American Axle & Manufacturing -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Nasdaq, Inc. (NASDAQ:NDAQ),...

NDAQ : 80.55 (-0.10%)
AXL : 15.90 (-2.45%)
PNW : 83.78 (+0.11%)
CALA : 5.85 (+0.52%)
NATI : 44.15 (-0.76%)
AVD : 16.86 (-1.52%)
Calithera Biosciences Highlights Breadth of Innovative Pipeline at R&D Day

-Updated response rate of 50% in advanced renal carcinoma treated with CB-839 + cabozantinib

CALA : 5.85 (+0.52%)
Calithera Biosciences to Host R&D Day and Webcast on October 5, 2018

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology...

CALA : 5.85 (+0.52%)
Recent Analysis Shows Ellie Mae, Organovo, Calithera Biosciences, Whirlpool, Marathon Oil, and Infinera Market Influences -- Renewed Outlook, Key Drivers of Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellie Mae, Inc. (NYSE:ELLI),...

WHR : 107.73 (-0.56%)
ELLI : 84.95 (-0.43%)
MRO : 20.40 (-2.35%)
CALA : 5.85 (+0.52%)
ONVO : 1.09 (unch)
INFN : 6.21 (-0.64%)
Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates

Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

CALA : 5.85 (+0.52%)
Calithera: 2Q Earnings Snapshot

SOUTH SAN FRANCISCO, Calif. (AP) _ Calithera Biosciences Inc. (CALA) on Tuesday reported a loss of $3.1 million in its second quarter.

CALA : 5.85 (+0.52%)
Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights

-Two Novel Programs Entering Clinical Development

CALA : 5.85 (+0.52%)
Calithera Biosciences, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Calithera Biosciences, Inc. (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 5:00 PM Eastern Time....

CALA : 5.85 (+0.52%)
Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018

Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology...

CALA : 5.85 (+0.52%)
Research Report Identifies Monster Beverage, Infinera, Zynga, Calithera Biosciences, Marathon Oil, and National Instruments with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Monster Beverage Corporation...

ZNGA : 4.16 (-0.95%)
MNST : 52.89 (+0.49%)
MRO : 20.40 (-2.35%)
CALA : 5.85 (+0.52%)
NATI : 44.15 (-0.76%)
INFN : 6.21 (-0.64%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade CALA with:

Business Summary

Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company's lead product candidate includes CB-839 which is in three Phase...

See More

Key Turning Points

2nd Resistance Point 6.09
1st Resistance Point 5.96
Last Price 5.85
1st Support Level 5.72
2nd Support Level 5.61

See More

52-Week High 18.35
Fibonacci 61.8% 12.89
Fibonacci 50% 11.20
Fibonacci 38.2% 9.51
Last Price 5.85
52-Week Low 4.05

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar